Accessibility Menu
CollPlant Biotechnologies logo

CollPlant Biotechnologies(NASDAQ) CLGN

Market Cap$7.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-98%
5 Year-98%
1 Year-86%
1 Month+37%
$0.37
-5.54%
-0.02Today
After hours$0.35-$0.02 (-4.48%)
CollPlant Biotechnologies last closing stock price
MetricPriceDate
Last closeUSD 0.372026-09-01
CollPlant Biotechnologies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+28.48%USD 0.292026-08-25
1 month+36.58%USD 0.272026-07-31
3 month-6.83%USD 0.402026-06-03
Year to date-73.39%USD 1.402025-12-31
1 year-85.78%USD 2.622025-08-29
3 year-94.58%USD 6.872023-09-01
5 year-97.91%USD 17.872021-09-02
Since inception-97.98%USD 18.472015-05-14

CollPlant Biotechnologies Financials at a Glance

Market Cap

$7.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$389.00K

Net Income (TTM)

-$13.13M

EPS (TTM)

-$1.03

P/E Ratio

-0.36

Dividend

$0.00

Beta (Volatility)

0.59 (Low)

Price

$0.37

Volume

7,104,964.186

Open

$0.35

Previous Close

$0.37

Daily Range

$0.32 - $0.41

52-Week Range

$0.26 - $3.18

Estimated Earnings Date

Aug 31, 2026

CLGN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd. is a pioneering enterprise in regenerative and aesthetic medicine, focusing on the three-dimensional (3D) bioprinting of tissues and organs. The company leverages proprietary plant-based genetic engineering technology to produce recombinant type I human collagen, offering innovative solutions across the United States, Canada, and Europe.

Products and Services
  • BioInks for 3D tissue and organ fabrication
  • Dermal and soft tissue fillers for aesthetic applications
  • 3D bioprinted and injectable breast implants for tissue regeneration
Growth Outlook
  • Strategic collaborations with industry leaders enhance market reach
  • Expanding product portfolio positions the company for future growth
  • Increasing demand for regenerative medicine solutions supports long-term potential
Financial Highlights
  • Recent quarterly revenue of $73,000 shows a slight increase from previous quarters
  • Cash and cash equivalents totaled $4.26 million as of March 31, 2026
  • Current ratio of 2.27 indicates strong short-term financial health
CollPlant Biotechnologies Ltd. operates in a rapidly evolving sector, with a focus on innovative solutions that address significant medical needs. The company's diverse product offerings, including advanced wound care treatments and soft tissue repair matrices, are designed to meet the growing demand for regenerative medicine. Recent financial data indicates a stable cash position, which may support ongoing research and development efforts. The strategic partnerships established with notable organizations further enhance the company's potential for growth and market penetration. As the demand for regenerative and aesthetic medical solutions continues to rise, CollPlant is well-positioned to capitalize on emerging opportunities in the biotechnology industry.
AI Generated • Aug 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

39

CEO

Yehiel Tal

Website

www.collplant.com

Headquarters

Rehovot, TA 7670104, IL

CLGN Financials

Key Financial Metrics (TTM)

Gross Margin

-319.28%

Operating Margin

-3329.05%

Net Income Margin

-3376.35%

Return on Equity

-160.28%

Return on Capital

-128.63%

Return on Assets

-143.03%

Earnings Yield

-2.78%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

18.91M

Volume

7.10M

Avg. Volume

3.17M

Financials (TTM)

Gross Profit

-$1.24M

Operating Income

-$12.95M

EBITDA

-$12.03M

Operating Cash Flow

-$11.58M

Capital Expenditure

-$26.11K

Free Cash Flow

-$11.60M

Cash & ST Invst.

$4.26M

Total Debt

$2.65M

CollPlant Biotechnologies Performance Analysis

CollPlant Biotechnologies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 299,000-98.1%
20232023-12-31USD 10,959,0003565.2%
20242024-12-31USD 515,000-95.3%
20252025-12-31USD 2,371,000360.4%
CollPlant Biotechnologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-91.3%
Q32025-09-30-57.0%
Q42025-12-31-22.1%
Q12026-03-3121.7%
CollPlant Biotechnologies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.53N/A
20232023-12-31USD -0.62-59.8%
20242024-12-31USD -1.45135.3%
20252025-12-31USD -0.94-35.1%
CollPlant Biotechnologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-115.4%
Q32025-09-303.6%
Q42025-12-317.4%
Q12026-03-318.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$73.00K

-96.4%

Gross Profit

-$243.00K

-115.0%

Gross Margin

-3.33%

N/A

Market Cap

$7.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$180.65K

N/A

Employees

39

N/A

Net Income

-$3.10M

-113.3%

EBITDA

-$2.89M

-139.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$4.26M

-60.3%

Total Debt

$2.65M

-6.8%

Accounts Receivable

$233.00K

-47.0%

Inventory

$679.00K

+0.9%

Long Term Debt

$1.86M

-12.1%

Short Term Debt

$794.00K

+8.5%

Return on Assets

-1.43%

N/A

Return on Invested Capital

-1.92%

N/A

Free Cash Flow

-$3.06M

-159.8%

Operating Cash Flow

-$3.05M

-161.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
XCURExicure, Inc.
$1.30-0.76%
SONNSonnet BioTherapeutics Holdings, Inc.
$1.26-59.35%
CVKDCadrenal Therapeutics, Inc. Common Stock
$1.51-13.71%
MTVAMetaVia Inc.
$1.72+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$14.06+0.06%
NVDANvidia
$217.44-0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.33-0.06%
INTCIntel
$88.97-0.01%

Questions About CLGN

What is the current price of CollPlant Biotechnologies?

CollPlant Biotechnologies is trading at $0.37 per share.

What is the 52-week range for CollPlant Biotechnologies?

Over the past 52 weeks, CollPlant Biotechnologies has traded between $0.26 and $3.18.

How much debt does CollPlant Biotechnologies have?

As of the most recent reporting period, CollPlant Biotechnologies reported total debt of $2.65M.

How much cash does CollPlant Biotechnologies have on hand?

CollPlant Biotechnologies reported $4.63M in cash and cash equivalents in its most recent financial results.

What is CollPlant Biotechnologies’s dividend yield?

CollPlant Biotechnologies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services